3,118 reports of this reaction
3.5% of all AZITHROMYCIN MONOHYDRATE reports
#3 most reported adverse reaction
DYSPNOEA is the #3 most commonly reported adverse reaction for AZITHROMYCIN MONOHYDRATE, manufactured by Aurobindo Pharma Limited. There are 3,118 FDA adverse event reports linking AZITHROMYCIN MONOHYDRATE to DYSPNOEA. This represents approximately 3.5% of all 89,541 adverse event reports for this drug.
Patients taking AZITHROMYCIN MONOHYDRATE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among AZITHROMYCIN MONOHYDRATE users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for AZITHROMYCIN MONOHYDRATE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 3,118 FDA reports for AZITHROMYCIN MONOHYDRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 3.5% of all adverse event reports for AZITHROMYCIN MONOHYDRATE, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking AZITHROMYCIN MONOHYDRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.